High-field (7T) MRI and genetic biomarkers for neurocognitive impairment in type 2 diabetes melltius - 7T in type 2 diabetes mellitus

niversiteit Maastricht0 个研究点目标入组 180 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•* Aged 40-75
•* Enrolled in existing *Maastricht Study* (M-Study)
•- Complete dataset available
•- Completed all four visits (including 3T MRI scan)
•* Gave written informed consent to the M-Study board to be approached for additional research;DM2:
•* Fasting blood glucose * 7.0 mmol/l, or
•* After an oral glucose tolerance test (OGTT) blood glucose * 11.1 mmol/l or
•* Used oral glucose-lowering medication or insulin;MetS:
•* Impaired glucose metabolism (IGM) with fasting blood glucose * 6.1 mmol/l or after an OGTT blood glucose * 7.8 mmol/l;In addition, participants should meet two out of 4 of the following criteria [35]:
•* Triglycerides * 1.7 mmol/l
•* HDL cholesterol < 1.3 mmol/l (women), < 1.0 mmol/l (men)
•* Blood pressure * 130/85 mmHg (or medication)
•* Waist circumference > 88 cm (women), > 102 cm (men);For age and gender matched controls:
•* No IGM and no more than 1 criterion of the metabolic syndrome
•* No cognitive impairment (MMSE score > 24)

•* Contra-indications for MRI examination: 1) pacemaker, 2) neurostimulator, 3) medication pump, 4) cochlear or hearing implant, 5) tattoos or other items that cannot be removed and include metal parts, 6) metal splinter in the eye, 7) pregnancy, 8) claustrophobia, 9) brain vessel clamps, 10) denture, which contains magnets, 11) operations in the past, where metal or synthetic material is used and still were in the body;
•* Psychiatric or other disorders likely to impact on informed consent;
•* Diabetes mellitus type 1 (DM1).

发起方